ORKA Insider Trading Activity and SEC Form 4 Filings
ORKA insider trading summary
Over the past 12 months, insiders at Oruka Therapeutics, Inc. (ORKA) reported 121 sales worth $1.54B by 11 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.54B.
Latest ORKA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sell | $236K (2,442 @ $96.70) |
| Nov 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sell | $74K (756 @ $97.45) |
| Nov 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sell | $30K (300 @ $98.40) |
| Nov 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sell | $613K (6,466 @ $94.77) |
| Nov 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sell | $1.4M (15,036 @ $95.64) |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sell | $77K (1,000 @ $77.20) |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sell | $30K (400 @ $74.90) |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sell | $323K (4,100 @ $78.79) |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sell | $38K (500 @ $76.12) |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sell | $238K (3,000 @ $79.49) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.